Psychedelic-assisted therapies could hit UK markets sooner than expected – and sooner than may happen in Europe – under a new government funding plan for innovative...
When psychedelic therapies begin to gain regulatory approval, they will need to be incorporated into the medical billing and coding system in a way that ensures...
Psychedelic substances, such as LSD and psilocybin, are known for their effects on the brain that can produce profound changes in perception, mood and consciousness.
In what has been described as a “historic trial”, ICEERS has suggested that the verdict of an ayahuasca trial in Mexico opens the door for the...
Breaking Convention is returning in 2023 to explore the latest groundbreaking psychedelic research and provide insights into law, politics, art, history and philosophy.
Psychedelics, also known as hallucinogens, are a class of psychoactive substances that alter perception, mood and cognitive processes.
In response to a letter from a group of cross-party MEPs calling for the EU to act fast on psychedelics, the European Medicines Agency will be...
Small Pharma has announced results from its Phase 2a trial of its intravenous formulation of DMT – SPL026 – demonstrating improvement in depression and anxiety.
Dr Devon Christie, Medical and Therapeutic Services Director with Numinus, speaks to Psychedelic Health about the representation of women in the field of psychedelics – from...
In this article, Nina Patrick, Ph.D.